Valneva announces launch of proposed global offering, start of the roadshow and Nasdaq listing
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
XENOTHERA’s anti-COVID XAV-19 treatment: the end of the POLYCOR inclusions clinical trial promoted by the Nantes University Hospital
The biotech XENOTHERA and the Nantes University Hospital announce the end of the inclusions of the second phase of the... View Article
Testing a new robot at Nantes University Hospital
A trial of the HUSKY-UV, a UV disinfection robot, took place in the Thoracic Endoscopy Unit at Nord Laennec Hospital... View Article
Research | CAR-T cells are revolutionising cancer treatment
LYSA (the lymphoma research group) has just launched the 1st French academic study of CAR-T cells. Named ALYCANTE, this study... View Article
Treatment of aneurysms and strokes (CVA): Rennes University Hospital has acquired a new-generation interventional imaging platform
Because every minute counts when a person suffers a stroke (CVA), since the start of the year Rennes University Hospital... View Article
Prevention, diagnosis, treatment: the power of Microbiota
Microbiota, a genuine repository of our lifestyle, is a key part of our health and Atlanpole Biotherapies has made it... View Article
Françoise Le Vacon
As a scientist in perpetual motion and endowed with inexhaustible energy, she has been developing her expertise in the field... View Article
OSE Immunotherapeutics enters into global license agreement in the organ transplantation market
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in... View Article
CELIS Challenges? Are you up to it?
In the framework of our European project CE4BIG, we have developed a collaboration with the European project CELIS, which is... View Article
GlioCure transforms into a Limited Liability Company and closes a new round of financing
GlioCure, a preclinical-drug-development company specialized in neuro-oncology, announced today that during a recent combined general meeting, its shareholders ratified transformation... View Article